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OF LEUKOPROLIFERATIVE STATES IN MAN**
The Epstein-Barr virus (EBV), is a herpes-like virus found in continuous
cultures of human leukocytic cells derived from certain tumors, from bone
marrow and peripheral blood leukocytes of patients with diseases such as
leukemia and infectious mononucleosis, and from the blood leukocytes of
some normal persons. EBV was discovered in lymphoid cell cultures origi-
nating from Burkitt's lymphoma (BL); because it was the first virus to
show a regular association with a human malignant tumor, it has received
a great deal of attention from experimental oncologists, virologists, epide-
miologists, and clinicians in the six years since its discovery.
The hypothesis that viruses are a cause of human malignant disease has
been explored with increasing energy since studies in lower animals have
demonstrated the oncogenic potential of these agents. The RNA tumor
viruses of chickens,' mice,2 and cats' have been considered likely models for
human leukemia and lymphoma because of the similarity of the diseases in
lower animals and in man, and because these agents produce tumors in the
species in which they are found in nature. Polyoma and simian virus 40
(SV40), small DNA viruses of the papova group, do not usually produce
tumors in their natural host but they are important tools in experimental
viral cancerigenesis, because they offer the promise of close genetic and bio-
chemical analysis of malignant transformation in vitro. Some types of human
adenoviruses, larger DNA viruses, cause tumors in experimental animals
and produce malignant transformation of animal cells in vitro.' Since some
adenovirus types are oncogenic and others are not, a great deal of research
has been directed toward understanding these differences which, at present,
are not fully explained at a molecular level.
More recently a fourth group of animal viruses, the herpes group, which
are still larger, more complex enveloped viruses with double-stranded DNA,
have been regularly associated with tumors both in lower animals and in
man. The herpes virus of the Lucke frog renal adenocarcinoma was dis-
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covered in the 1930'se and its morphology described in 1956.' In the last
year its oncogenic capacity was demonstrated experimentally by the induc-
tion of tumors on the mesonephric ridge of tadpoles.7 A herpes virus has
been found in Marek's disease, a lymphoma of chickens; the agent cultivated
in tissue culture is able to reproduce the disease upon inoculation of suscepti-
ble birds.8 Preliminary field trials of an attenuated virus vaccine suggest that
this commercially important avian tumor can be prevented by immunization.9
In the past year Melendez and his co-workers'0 reported that herpes virus
saimiri, indiginous to the squirrel monkey, produces lymphoma and oc-
casionally leukemia on inoculation into cotton top marmosets and owl
monkeys, two other South American primates. Finally, two herpes viruses
of man, the genital strain, or sub type 2 of herpes virus hominis,' and EBV
have received attention as possible tumor inducers.
These examples of the close association of herpes viruses with tumors
have widened interest in EBV as a candidate human-tumor virus. Further-
more, in early 1968, W. and G. Henle and their collaborators reported that
an immune response to EBV developed during the course of infectious
mononucleosis (IM).' The association of the virus with this long enigmatic
disease, which to some appeared as an abortive malignancy, has generated
even more interest.?s
For reasons which will be discussed, it is not possible to state with abso-
lute certainty that EBV is the cause of Burkitt's lymphoma or infectious
mononucleosis, the two conditions with which it has been associated most
closely. Students of this virus have become polarized into two camps; one
group proposes that EBV is the etiologic agent of IM, and perhaps a co-
carcinogen with some other factor in BL; the other group considers that
EBV is a passenger virus with an attraction for poorly differentiated
lymphoblastic cells. It is the purpose of this review to analyze the published
information about the virus and to attempt to correlate the available evidence
with the central question of whether the virus is pathogen or passenger. No
attempt has been made to review the clinical aspects, pathology, or therapy
of BL or IM, both of which have been comprehensively described in mono-
graphs recently published."" Instead, attention will be focused on the be-
havior of EBV virus in vitro and on serologic and epidemiologic studies of
EB virus infection.
Discovery of EBV and its association with Burkitt tumor cells
In 1958, Burkitt made his original observations on an unusual tumor of
the jaw occurring in children of Uganda.' The geographic distribution of
the disease was of special interest; the disease predominated in hot, wet low-
lands. Because this pattern coincided with the distribution of arthropod
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vectors, Burkitt considered that a mosquito-borne agent might be the cause.
Accordingly, specimens of tumor tissue were submitted to several virologic
facilities, where a variety of microorganisms, including reovirus,17 herpes
simplex virus"8 and mycoplasmas," were recovered, although none were iso-
lated regularly. In late 1963, Epstein, Barr, and Achong established several
continuously growing in vitro cell lines with lymphoblastic features from
specimens of tumor tissue.` Some characteristics of these human lympho-
blastoid cell lines (HLCL) were morphology suggesting an immature state
of the lymphocyte series, continuous rapid growth after 4-8 weeks in cul-
ture, and failure to adhere to glass. Several cell lines examined with the
electronmicroscope revealed virus-like particles of a size and structure char-
acteristic of the herpes group.' Such particles were generally identified in
only a small proportion of the in vitro cell population.
Origin of continuous lines of lymtphoblastoid cells and presence of
EBV therein
Soon after Epstein and his associates established cell culture lines from
Burkitt lymphoma, such cell lines were derived from patients with a variety
of diseases and examined for viral particles by electronmicroscopy and later
for viral antigen by the immunofluorescent (IF) assay on fixed cells (Table
1). Lymphoblastoid cell lines were grown from BL by several workers and
nearly all contained EB viral particles.`"t The major exception was a BL
line designated Raji' which, despite extensive examination, has not revealed
complete virus.
Itakawa and Grace' and Foley and co-workers? found that HLCL could
be established from peripheral blood leukocytes of leukemia patients. Even-
tually HLCL were derived from the peripheral blood of patients with acute
leukemia of the myeloblastic'° and lymphoblastic types' and from patients
with acute and chronic myelogenous leukemia.'-" HLCL originating from
patients with acute leukemia often, though not invariably, contain EBV
virions. Moore and his co-workers found herpes-like particles in lines from
acute leukemia ;' three lines derived in our laboratory from children with
leukemia contain EBV antigen. Certain HLCL from leukemia patients do
not contain EBV antigen or particles, such as the CCRF-CEM line, which
has been extensively studied by Foley and co-workers.'
Lymphoblastoid lines were also derived from lymph node biopsies of
reticulum cell sarcoma, mycosis fungoides, Hodgkin's disease, multiple
myeloma, carcinoma of the lung, and from a spleen removed because of
hereditary spherocytosis.M'5
Continuous culture of cell lines from the blood of patients with IM was
reported by Pope in 1967,' by Glade and co-workers in 1968, and in 1969
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by the Henles.' DiehlM and Moses, et al." demonstrated in a series of cases
that blood leukocytes from patients with IM grew readily in the acute phase
of the disease and frequently, though not invariably, during convalescence
or many years later. Most HLCL derived from patients with IM contain
detectable EBV.""
Lymphoblastoid lines have been grown from peripheral blood of patients
with other viral illnesses associated with circulating "atypical" lymphocytes.
Glade and his associates and Stevens, et al. found that blood leukocytes from
about half of patients with presumed viral hepatitis grew into HLCL.""' All
patients in Glade's series had EBV antibody when their leukocytes were
cultivated in vitro. Two of the lines established by Glade from hepatitis pa-
tients showed evidence of EBV. Minnefor and co-workers established long-
term suspension cultures of leukocytes from patients with viral diseases
such as herpes simplex, mumps, herpes zoster, and measles, but did not pro-
vide data about EBV antibody in their patients.' Klemola, et al. found that
in 3 of 12 adult patients with cytomegalovirus infection HLCL have been
obtained from 6 months to several years after appearance of the clinical
disease.'
In few series has a large control group of normal individuals been studied
in order to compare the frequency of formation of HLCL in a particular
disease and in normals. Such information as is available, including results
from our laboratory, suggests that when small inocula of cells (105_106 cells/
ml.) and small volumes of cells (10-20 ml.) are used, normal blood leuko-
cytes do not spontaneously form HLCL. By contrast, white blood cells from
patients with IM and from some patients with leukemia form lines readily
under these conditions. However, under special conditions white blood cells
from healthy individuals who possess EBV antibody can be grown as
HLCL. Long-term cultures of leukocytes from normal individuals were first
described by Moore" and later by Gerber and Monroe.' Both workers ob-
served EBV in some of these cell lines. The experimental method in large
part influences whether or not lymphocytes from normal persons can be
grown as HLCL. Both Moore and Gerber and Monroe initiated normal
blood cultures with white blood cells from 500 ml. of blood, and frequently
adjusted the leukocyte concentration so that at least 5 X 105 viable cells/ml.
were always present.
Several reports of serial attempts to cultivate HLCL are summarized in
Table 1. HLCL have been derived from patients with a variety of diseases,
malignant and benign, and under special cultural conditions from normals.
The majority of such leukocyte suspension cultures have contained EB virus,
and whenever it has been studied the donor of the leukocyte line has had
detectable EBV antibodies. A reasonable general hypothesis under which to
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assemble these observations is that a very small number of cells with the
capacity to divide continuously in vitro is present in the peripheral blood of
normal individuals with EBV antibodies and that in diseases such as leu-
kemia or IM the number of such cells competent to initiate DNA synthesis
in vitro increases.
Significance of EBV "free" lines
A line "free" of detectable EBV poses many interesting questions, such
as "Was EBV initially responsible for its growth?" or "Is EBV present in
the line in some form not detectable by our current limited assay tech-
niques?" Detection of EBV is difficult since viral particles or viral antigens
are present in a small proportion of cells. Detection of virus by electron-
microscopy represents a serious sampling problem. In IF tests unwanted
fluorescence in certain lines due to production of gamma globulins makes a
low level of immunofluorescence difficult to interpret. Another problem in
detection of EBV is the downward fluctuation with time in the level of im-
munofluorescent cells due to unknown causes.
A final answer to the question, "Do all HLCL contain at least part of the
EBV genome?" must await development of more refined techniques to
demonstrate presence of the viral genome. A recent study by Zur Hausen
and co-workers,' employing techniques of nucleic acid hybridization, sug-
gests that viral genome is present in some HLCL, such as the Raji line,
which do not reveal particles or viral antigen. Zur Hausen and collaborators
showed that the Raji line contained DNA with homology to purified EB
viral DNA. Furthermore, in preliminary experiments they found an RNA
in Raji cells which hybridized with EB viral DNA. This result suggests
that at least part of the EB viral DNA in Raji cells is transcribed into RNA.
Characteristics of the EB virion-Morphological and biophysical
EBV in electronmicrographs resembles herpes simplex virus, though it
is smaller.'7 Encapsidated forms with or without an electron dense nucleoid
are seen in the cell nucleus. The approximate diameter of the electron dense
central nucleoid is 45 nm, and of the capsid plus nucleoid, 70 nm. Some en-
veloped forms are found in the cell cytoplasm, but rarely extracellularly. The
diameter of the completed enveloped virion is approximately 115 nm. Most
particles seen in an infected cell are imperfect; they either are unenveloped,
or contain no nucleoid core; occasionally free nucleoids are seen. In early
pictures of virus from Burkitt tumor cells, extracellular virions were en-
closed in a hazy cloud of amorphous material, thought to be specific antibody
coating since these early HLCL cultures contained human serum.
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Cells harboring the herpes-like particles are usually degenerated, although
occasionally particles are found in morphologically altered but intact cells.
The nuclear membrane of virus-infected cells frequently shows segments of
reduplication, a morphological sign of infection with many other herpes
viruses. In addition, infected cells demonstrate collections of tubular struc-
tures located in the cytoplasm.'7
EBV particles were partially purified from infected cell lines by Toplin
and Schidlovsky' who submitted homogenates of a large number of cells to
rate zonal centrifugation. Several grossly visible bands were isolated that
contained viral particles in various stages of maturation, similar to those
present in thin sections of infected cells.
The DNA of EBV has been purified and its density determined.`6 Iso-
topically labelled virus was first isolated either from supernatant fluids or
cell extracts by rate zonal centrifugation in sucrose gradients. The virus was
then extracted further, and the labelled DNA was placed on an equilibrium
buoyant density gradient of cesium chloride. In three laboratories the density
of EB viral DNA was between 1.716 to 1.720 gm/cm.3 This value is similar
to that obtained for herpes simplex DNA, and significantly different from
cell DNA (1.695 gm/cm3). DNA of the density corresponding to that of
EBV was not obtained when the Raji-line, free of EBV particles, was
treated in parallel, although, as previously mentioned, EB viral DNA can
be demonstrated in the Raji line by nucleic acid hybridization.
Assays for the presence of EBV
Sensitive quantitative assays for the biologic activity of EBV, such as
the plaque assay employed for other animal viruses, are not yet available.
For this reason, little is known of the replicative cycle of the virus. However,
several existing assays detect the presence of EBV.
Electronmicroscopy: Hinuma and co-workers' studied growth of EBV
in a BL line by sampling the cells and supernatant fluids at intervals and
counting particles by electronmicroscopy. Their results suggested that the
majority of the virus was cell-bound but that some was released into the
fluid phase of the culture as the cells were kept without refeeding.
Intracellular EBV antigen: Assay for the virus was simplified by the find-
ing that most adult human sera contained anti-viral antibodies detectable
by the indirect IF test on cells previously subjected to acetone fixation.3' The
frequency of fluorescent cells correlated with the number of cells containing
viral particles in electron micrographs and certain lines without viral parti-
cles were also free of viral antigen by the IF test. Increased specificity of the
IF test was achieved by preparation of anti-EBV sera in rabbits and con-
jugation of the sera with fluorescein isothiocyanate.' When individual cells
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were studied both by electronmicroscopy and by the IF test, cells which con-
tained viral antigens also contained particles. The IF test is at present the
most widely employed assay both for determination of EBV antibody levels
in human sera and also for detection of the presence of EBV in various
HLCL.
Membrane antigen: Another assay detects an antigen on the cell mem-
brane of unfixed HLCL cells and is called the membrane immunofluores-
cence (MIF) test.' MIF antigen has been found on the surface of cells in
HLCL derived from patients with Burkitt's lymphoma, IM, leukemia, and
from normals. By contrast to the intracellular IF antigen, which has only
been found in cells grown for a time in vitro, the MIF reaction can be
demonstrated on cells taken directly from biopsy material as well as those
grown in culture.
The MIF antigen is distinct from antigens responsible for leukocyte typ-
ing; it can be demonstrated by using a patient's own serum to test his own
tumor cells.'7 The MIF reaction is probably due to more than a single new
antigen at the cell surface.'M Evidence for multiple antigens comes from ex-
periments in which sets of sera with MIF reactivity are compared for their
capacity to block the MIF reaction of other sera.
The MIF antigen and the intracellular EBV antigen are distinct antigen-
antibody systems, for MIF antibody can be removed by absorption with
whole cells from an HLCL; after absorption, antibody against intracellular
antigen persists.5M In contrast to the low level of intracellular antigen, often
as many as 50% of cells may contain surface antigens. However, there ap-
pears to be some correlation between the extent of the MIF reaction and the
extent of IF staining for intracellular viral antigen in a given HLCL.'
These results suggest that the extent of expression of the viral genome
varies from one HLCL to another and that regulation of membrane antigen
and of viral antigen may be coordinated to some extent.
The implication of studies to date is that the MIF detects an antigen
coded by viral genome. However, this point has not been proved conclusive-
ly and the alternative, that it represents an "unmasked" cellular antigen,
must be explored.'
Complement fixation (CF): Extracts of certain BL or leukemia cell lines
contain antigens that fix complement in the presence of certain human and
primate sera."' At least two CF antigens are present in EBV-infected
HLCL."T One antigen (V antigen) is associated with viral particles; the
other antigen (S or soluble antigen) is present in supernatant fluids from
which virus has been sedimented by ultracentrifugation. The CF test appears
to be specific for EBV, since positive sera do not fix complement with anti-
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gens prepared from normal human leukocytes, a variety of non-leukocytic
tissue cultures, or antigens prepared from other herpes-group viruses.
Immunodiffusion: Precipitating antigens are found in highly concentrated
preparations of aged cultures of the Jijoye line of BL lymphoblasts.' In
further applications of this technique as many as three lines of reaction be-
tween various sera and the Jijoye line were found.' Agar gel immunodif-
fusion correlates well with the IF method on fixed cells, and with CF, for
detection of EBV.' However, of the three methods, immunodiffusion is the
least sensitive.
Biologic activity of EBV
Two biologic properties of EBV can be studied in cell culture. First, ma-
terials containing EBV cause normal leukocytes to undergo transformation
into continuous cell lines of lymphoblastoid character. Second, highly con-
centrated, partially purified preparations of EBV may superinfect HLCL
that are initially devoid of EBV antigens.
Transformation of normal leukocytes into continuously growing cell lines
by EBV was discovered by Henle and co-workers.' As a source of EBV,
Henle used lethally x-irradiated cells of the BL Jijoye line, and as a source
of normal leukocytes the peripheral blood white cells of infant girls. (The
Jijoye line maintained a diploid male karyotype and thus the origin of cells
growing in co-cultivation could be identified by examination of chromo-
somes.) After two to three weeks of co-cultivation of the x-irradiated Jijoye
cells and the female leukocytes, in the presence of a human diploid fibroblast
"feeder layer," lymphoblastoid cell lines developed. These lines had female
sex chromosomes (thus were derived from the infant leukocytes) and
contained EBV antigen. Under the conditions of the experiment, the x-
irradiated Jijoye cells in separate culture did not survive, nor did the female
leukocytes. As acontrol, x-irradiated cells of the Raji BL line, without EBV
antigen, were incapable of promoting continuous growth of normal leuko-
cytes. Using a similar co-cultivation system, Miller and co-workers showed
that a factor capable of inducing continuous growth of normal adult leuko-
cytes was also present in the x-irradiated cells of an EBV-infected HLCL
from a leukemic child.' Similarly a leukemic cell line without EBV antigen
was incapable of inducing normal white blood cell transformation.' Further
studies by Diehl and co-workers and by our laboratory with this system have
shown that transformed normal leukocytes (TNL) are capable of inducing
continuous growth of other normal leukocytes.m Since EBV antigen appears
in the TNL, the hypothesis considered most likely is that the transformation
results from infection of the normal leukocytes by EBV and alteration of the
cell's growth regulation by the virus.
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This thesis is supported by the findings of J. H. Pope and his co-workers
in Brisbane, Australia, who showed that cell-free filtrates prepared from
extracts of a leukemic HLCL, containing EBV, were capable of inducing
continuous growth of leukocytic cells from human fetal thymus or spleen.'
Appropriate controls indicated that the fetal lymphocytes did not proliferate
in the absence of filtrates containing EBV. Sera that contained EBV anti-
bodies inhibited the transformation, and sera devoid of such antibodies had
no effect.' Neutralization of EBV-induced transformation of adult leuko-
cytes by immune sera has recently been demonstrated in our laboratory.'
Gerber, et al. have found75 that EBV concentrated and purified from super-
natant fluids of aged cultures induced continuous growth of leukocytes ob-
tained from an adult who had no evidence of past experience with any mem-
ber of the herpes group. The mechanisms of EBV-induced leukocyte trans-
formation remain to be elucidated.
Extracts of infected HLCL have been placed in a wide variety of tissue
culture systems and a large number of experimental animals, without con-
sistent cytopathic or other effects.'7 In preliminary reports it appeared that
EBV might be cytopathic for dog thymus cells' or that EBV-infected cells
might cause an encephalitis in newborn thymectomized hamsters;' however,
these reports have not been confirmed.
Horoszewicz found that concentrated and purified virus obtained from
the fluid phase of infected cell lines when transferred to other HLCL ap-
parently devoid of EBV, produced IF antigen in the recipient cells.' Various
cell lines free of antigen have been used as receptors for the virus.'-' It has
not been resolved whether viral antigen that appears in the "negative" lines
is due to the superinfecting agent or to reactivation of latent virus in the
recipient line, although the former explanation appears most likely. The
activity of virus preparations used to "superinfect" is very low (102 to 103
ID50/ml.) despite concentration of up to 1,000-fold in some instances; the
reasons for this have not been adequately explained.
Superinfection of the Raji line with concentrated partially purified EBV
forms the basis for another serologic test, called the early antigen assay.'
When the superinfected Raji line is treated with certain normal human sera
in an immunofluorescence assay a very small number of EBV-infected cells
is detected (< 1%). By contrast, when sera of comparable anti-EBV titer
from patients with BL or nasopharyngeal cancer and from some IM patients
are used, a larger number of EBV-superinfected cells (as many as 50%o)
are detected. The superinfected Raji cells are said to be "abortively infected"
because the EBV infection does not spread in the culture. Sera from some
patients detect this abortive or early antigen while sera from other persons
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such as convalescent IM patients or apparently healthy people do not detect
the antigen.
Relationship of EBV genome to individual cells of HLCL
Viral particles or viral antigens detectable by the IF test are present in
few cells of any HLCL, usually not more than 5%o and often less. The num-
ber of fluorescent cells in some HLCL can be increased by cultivation of the
cells at 320 C.,' or by cultivation of the cells in a medium deficient in L-
arginine." No published information is available on the effect of other tech-
niques that induce replication of temperate bacteriophage or that induce
replication of SV40 in transformed cells such as x-ray, Mitomycin C, or cell
fusion.
Several interpretations may be considered to explain the constant low
level of EBV infection in HLCL. The first is that HLCL are "carrier cul-
tures" for EBV; that is, a few infected cells in the culture produce virus
that infects the other cells. The low level of infection is explained by the
presence of interferon which may protect the cells." The second is that the
cultures consist of two distinct populations of cells: EBV-infected and -un-
infected; both populations give rise either to EBV-infected or -uninfected
cells. These two schema each assume that a very small proportion of cells
are actually infected at any one time. A third model, which has received ex-
perimental support recently,8`'t is that all cells in an EBV-infected culture
contain viral genome but only a small proportion of cells spontaneously make
viral particles or viral antigens. Experimental proof depended on methods
for growing mass cultures of HLCL from isolated single cells. Single cell
clones were derived from various HLCL, each of which contained approxi-
mately lgo of cells with viral antigen. The clones were treated with EBV
anti-serum to neutralize any virus that might be present at the cell surface.
Each clone tested showed evidence of EBV, thus suggesting that EBV in
some form is associated with all the cells in the culture.
Are HLCL tumor cellsf
It has not yet been determined whether the cells that comprise a HLCL
are tumor cells or whether they are "activated" normal lymphocytes. The
question is difficult to resolve for definite morphologic, biologic, or bio-
chemical markers among HLCL derived from normal blood, from patients
with IM, and from patients with malignant lymphoma or leukemia have not
been recognized. Attempts to study the problem of tumorigenicity has in-
volved transplantation of HLCL into heterologous hosts, such as newborn
ratse and newborn hamsters, which have been immunologically crippled with
antilymphocyte serum."' After several passages in hamsters, the tumor cells
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retain human surface antigens. Whether heterotransplantation represents
oncogenic potential or adaptation of the cells to an in vivo culture system is
not yet clear.
SEROLOGIC AND EPIDEMIOLOGIC STUDY OF EBV INFECTIONS
Three aspects of the human immune response to EBV have been studied;
namely, circulating antibodies to surface membrane antigens on intact virus-
infected cells, cell mediated reactions and circulating antibodies to the virus
per se or to virus-associated antigens.
Antibodies against surface antigens of HLCL have been found in sera
of BL patients and IM patients.' In a single reported case of BL, membrane
antibodies were examined sequentially. They were elevated during remission
induced by chemotherapy, after which they fell to a low level before recur-
rence of the disease.' Whether recurrence was related to disappearance of
the membrane antibodies is speculative. The actual biologic function of mem-
brane antibodies is uncertain, and it is not known whether or not the mem-
brane antibodies are cytotoxic in vivo.
Recently Fass and co-workers' found that some patients with BL de-
veloped delayed type hypersensitivity skin reactions to autologous tumor
cell extracts. In only one of 12 patients was the skin test positive before
treatment, but in 7 of 12 patients delayed cutaneous hypersensitivity to ex-
tracts of their own tumors was evident after clinical remission was induced
by chemotherapy. In several patients who failed to improve with treatment,
delayed skin reactions did not develop. The nature of the antigens responsi-
ble for the skin reaction is not known.
Very little published work concerns in vitro tests for cell-mediated im-
munity to EBV. Recently Steel and Hardy" and Junge, et al." reported that
extracts of cell lines formed from the peripheral blood of patients with IM
stimulate short-term DNA synthesis in primary cultures of lymphocytes
from the same patient. The nature of this mitogenic factor is not clear but
preliminary studies by Junge suggest that it is not virus, but has the char-
acteristic of a membrane-bound antigen.
When serological methods for detection of EBV antibodies became avail-
able in the mid-1960's, it was of greatest interest to determine whether the
presence of antibodies to EBV correlated with those disease states, specifi-
cally BL and leukemia, in which EBV could be frequently found in long-
term leukocyte cultures. Some results from these early serologic surveys,
done with various techniques, gave in general the same over-all picture, as
illustrated by the accompanying Table 2. A high frequency of EBV was
found with all methods in patients with BL. Similarly, nearly all sera of
African, Chinese, and American patients with nasopharyngeal cancer con-
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tained EBV antibody. The frequency of antibody titers in sera of leukemia
patients was much lower than in the other two diseases. A most surprising
finding from initial studies was that antibody was widely distributed in the
sera of healthy individuals, both African and American, although patients
with BL and IM, and nasal tumor have usually had significantly higher an-
tibody titers than normal individuals.
Age and geographic patterns of antibody
In a study of complement-fixing antibodies to EBV, Gerber' showed that
the age-distribution was similar to the pattern observed for other acute viral
diseases of childhood such as measles or poliomyelitis in the pre-vaccine era.
Nearly all sera from newborn infants contained antibody, presumably ma-
ternal in origin. Less than 20% of sera from infants aged 6 months to 1 year
contained antibody. With increasing age, the percentage of sera with anti-
body rose from 30%o in the 1 to 2 year group to more than 60% in the 3 to
5 year group. Porter and associates demonstrated a similar increase in the
prevalence of EBV antibodies with increasing age.'
Henle and Henle have examined sera taken prospectively to determine
whether the acquisition of antibody in the younger child was accompanied
by an identifiable clinical illness such as "non-bacterial tonsillitis."" In most
cases seroconversion to EBV was clinically silent.
The age at which antibody to EBV is acquired is influenced by geographic
and by social factors. Eighty percent of the African children studied by
Henle, et al.' possesed EBV by age 2, while a majority of 10 year old mid-
dle-class children from Cleveland, studied by the same workers, had no anti-
bodies." In their studies of Yale college students, Niederman, Evans, and
collaborators'-1' found approximately 60-75 o of freshmen to be suscepti-
ble to EBV. This figure, significantly higher than predicted by Gerber's
earlier serologic survey using sera from low-income families, was attributed
to the social-class background of college students. By contrast to their find-
ings in Yale undergraduates, Niederman and co-workers found only 257%o
of University of Philippines undergraduates without EBV antibodies.
Although large-scale geographic surveys have not yet been done, anti-
bodies have been found in sera collected from several isolated primitive peo-
ples from New Guinea, Micronesia, and South America."
A most important point which has received preliminary study1' is the
relationship between the distribution of Burkitt's tumor and the distribution
of EBV antibodies. EBV antibodies are no more frequent in residents of the
lowlands of Uganda where BL is endemic than in those living in other geo-
graphic areas where the tumor is much less frequent.
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Relationship of EBV to infectious mononucleosis
In late 1967 Henle, Henle, and Diehl discovered a relationship between
EBV and IM through observations during the illness of their laboratory
assistant, Elaine H.' Elaine H.'s leukocytes, used as controls in experiments
before she acquired IM, failed to proliferate for more than a short time.
After IM, her leukocytes grew continuously and contained EBV. Her
serum, free of EBV antibodies before her illness, contained EBV antibodies
after her illness. A small series of pre- and post- IM sera obtained from Dr.
Niederman at Yale, confirmed the observation that EBV antibodies were
absent in pre-illness sera and present in sera taken after the illness. Also
with Niederman's sera, Gerber and co-workers demonstrated with comple-
ment fixation that EBV antibodies were absent in pre-IM sera and that
they appeared during the disease,1' while in the same paired sera no con-
sistent response to herpes simplex, cytomegalovirus (CMV), or reovirus,
was observed. Absorption of sera with sheep red blood cells had no effect on
EBV antibodies, although heterophile antibodies were removed. Niederman
and his collaborators'0' showed that EBV antibodies appeared during the
clinical illness and persisted thereafter, while heterophile antibodies declined.
In an elegant epidemiologic analysis'0' made possible through a long-term
prospective collection of sera, Evans, et al. showed that the absence of EBV
antibody correlated well with susceptibility to IM, and conversely that col-
lege students who possessed EBV antibody at entrance did not develop IM.
In this investigation they established that occasional cases of heterophile-
negative IM were associated with antibody rises to EBV. Their data sug-
gested, furthermore, that inapparent infection with EBV was considerably
more frequent than clinical IM in persons younger than college-age, thus
confirming the hypothesis proposed ten years earlier by Evans.' By con-
trast, in the college-age group clinical IM was approximately twice as fre-
quent as inapparent infection with EBV. Other investigators have confirmed
that EBV antibodies develop during clinical IM,'0 though they disagree
about the significance of these antibodies. The complex question of their
significance will be treated in the DISCUSSION.
Klemola and Kaariainen'7 found rising complement-fixation antibody
titers to CMV in certain clinical cases of heterophile-negative cases resem-
bling IM, but usually distinguished by the absence of sore throat and wide-
spread lymphadenopathy. It was subsequently shown that CMV could fre-
quently be isolated from these patients. Klemola, Von Essen, Henle, and
Henle'0' recently studied 44 cases diagnosed as heterophile-negative IM.
Their results showed that CMV and EBV each cause some cases diagnosed
372
Volume 43,June, 1971E-B virus, a rezJiew M
as heterophile negative IM and that possibly other agents as well are re-
sponsible for a proportion of the cases.
Transmission of EBV infections
The route of transmission of EBV infections is in large part unresolved.
It has been presumed that IM is transmitted by the oral or respiratory route
but EBV has not been isolated from these sites. The failure to isolate EBV
from the upper respiratory tract may reflect the insensitivity of available
methods for cultivation of infectious virus. Attempts to isolate EBV from
mosquito pools in Africa have not met with success. This also may be a mat-
ter of technique. There is no evidence of congenital EBV infection in the
form of isolations of the virus from embryonic sites or from leukocytes of
newborn infants. Limited data collected by the Henles in the Cleveland
family study failed to detect individual infants whose maternal antibodies
did not disappear.
Transmission of EBV through blood transfusion has been docu-
mented.'`m Gerber called attention to rising EBV antibody titers in five
individuals of alarge series of patients who were treated with multiple blood
transfusions during and after open heart surgery. EBV was cultivated in
the leukocytes of one patient who developed an illness similar to IM, with
fever, atypical lymphocytes, and a positive heterophile test. Blacklow and
co-workers studied a similar case of post-transfusion mononucleosis in a
very elderly patient who ocquired an IM-like illness with heterophile anti-
bodies five weeks after receiving three blood transfusions for a hip fracture.
EBV was isolated from this patient and Ig-M anti-EBV antibodies were
present in her acute phase serum. Henle and others showed in a large pros-
pective series of patients receiving multiple blood transfusions for heart
surgery, that of 18 without pre-operative antibodies, six acquired EBV an-
tibodies, although none of the patients in this series developed illness clini-
cally similar to IM. Parenteral transmission of the virus probably occurs in
association with infected leukocytes in blood; however, other routes will
have to be sought for transmission of the majority of EBV infections in
which there is no evidence for parenteral exposure.
DISCUSSION
Intrinsic biologic interest of EBV
EBV is in many ways a unique virus, and will undoubtedly continue to
receive attention from those interested in the mechanisms of viral infections.
Thus far it shows strict tropism for primate leukocytic cells of the lympho-
cytic series. Tropism for cells of certain species in vitro and in vivo have
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been long recognized as a property of animal viruses, for example, in the
rather strict preference of poliovirus for primate cells. However, strict pref-
erence for one type of differentiated cell is a new phenomenon and deserves
further analysis.
Another feature of EBV infection at the cellular and molecular levels of
general biologic interest is the regulation of production of complete virus.
In vivo viral particle production is repressed, but in vitro virus is produced.
In cloned cell populations a few cells produce viral particles; most do not,
even though all cells apparently contain viral genome. The control mecha-
nisms, whether they reside in cell or virus, are closely regulated since ap-
proximately the same percentage of cells produce viral particles when the
cells are examined at random over a long period of time. A study of the
nature and mode of operation of repressors of virus synthesis in EBV in-
fected cells may have general relevance to problems related to cell differen-
tiation.
EBV causes changes in the morphology and growth characteristics of
normal leukocytes. It is not yet known whether this phenomenon is analo-
gous to "viral transformation" induced by polyoma virus and SV40, or
whether it is a further stage of "blast transformation" produced by sub-
stances such as phytohemagglutinin or by specific antigens. The former ex-
planation seems more likely at present than the latter. Whatever the explana-
tion, it will be of great interest to know the details of the mechanism by
which the normal lymphocyte with limited potential for in vitro growth is
stimulated to grow continuously by EBV.
In many ways, except for their in vitro immortality, the lymphoblastic
cells of HLCL resemble "dedifferentiated" lymphoblasts produced by phyto-
hemagglutinin (PHA). Both PHA-treated cells' and HLCL spontaneously
release interferon-like viral inhibitors."' Release of interferon may be re-
lated to the presence of viral or other inducers within the leukocytes, or the
release of interferon may occur whenever certain lymphocytic cells are in the
blast stage. The latter explanation does not account for the observation that
various HLCL differ considerably in the amounts of interferon which they
produce.' The availability of cell lines that continuously manufacture and
secrete interferon should allow analysis of the biosynthetic pathways in-
volved in interferon production. Similarly, the availability of a large variety
of HLCL which release immunoglobulins spontaneously' should permit
analysis of the mechanisms of biosynthesis of these important proteins. Spe-
cific antibody activity has not yet been assigned to the immunoglobulins
synthesized in vitro by HLCL.
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Does EBV cause infectious mononucleosis?
There are two major hypotheses about the role of EBV in IM. The frame-
work of the first hypothesis follows: EBV is mainly transmitted by the
respiratory route. Infection in the young child is associated with either no
clinical symptoms, mild febrile illness, or infrequently, IM. In older adoles-
cents and in susceptible adults infection with EBV more frequently causes
IM than inapparent infection. Heterophile-positive IM is accompanied by
development of EBV antibodies. Antibodies against the complete virus per-
sist for life, and whether they are acquired following IM or following in-
apparent infection, these antibodies protect against subsequent IM due to
EBV. After infection the virus also probably persists in lymphoid cells for
life.
Outlines of the second hypothesis may be summarized as follows: EBV
is a ubiquitous virus with a predilection for lymphoid cells. Its mode of trans-
mission is not known, but it may be congenitally acquired. It persists in
lymphoid cells in defective form, perhaps as viral nucleic acid, only until
lymphoid cells are transformed into blastic cells. In its defective form the
virus stimulates either a very low level or no antibody. When lymphoblasts
appear, due to one of many causes, complete virus proliferates and circulat-
ing antibodies to the virus are produced. According to the second hypothesis,
EBV antibodies correlate with resistance to IM because they co-exist with
antibodies for other agents which are truly responsible for the disease.
The available evidence favors the first hypothesis. The strongest link in
the chain of evidence in favor of a causal role for EBV in IM is the
demonstration by Niederman, Evans, and colleagues that absence of anti-
bodies against EBV correlates with susceptibility to IM. The evidence is
strengthened by the in vitro demonstration that EBV stimulates leukocyte
proliferation, a basic pathologic change in IM. The reported cases of EBV
infection and post-perfusion illness transmitted by blood, after a five-week
incubation period, also favor a direct role of EBV in the IM syndrome. Ex-
perimental transmission of IM to patients with malignant disease has ap-
parently been accomplished, although published details are few.' In general,
the major elements lacking to fulfill Koch's postulates are experimental re-
production of disease in man or laboratory animals, and recovery of the or-
ganism from experimental disease. These requirements may be very difficult
to achieve. For a variety of reasons, especially ethical, it may prove impos-
sible to carry out experimental transmission studies in man. EBV may or
may not be ultimately adaptable to an animal host. An objection to the
hypothesis of direct causation is that EBV has not been recovered immedi-
ately from materials obtained from persons with the disease. It has only
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been found in leukocytes which have been cultured in vitro for several weeks.
However, the intimacy of certain cell-virus relationships may require ad-
justments of the definition of "viral isolation," as recent experience with
measles virus and subacute sclerosing panecephalitis has taught us.'
The passenger theory very correctly indicates areas where information
is lacking: there is nearly no data on the usual route of transmission of EB
virus and no suitable animal model for study of the in vivo effects of EB
virus. One observation central to the passenger virus thesis is the frequent
association of EBV with a number of diseases, besides IM, in which there
are either circulating atypical lymphocytes or tissue lymphoblasts. The thesis
states that EBV proliferation occurs when such cells are present. However,
available evidence suggests that atypical lymphocytes per se are not sufficient
to activate EBV infection. McCollum and co-workers'7 studied serial serum
specimens from children with experimental hepatitis, some of whom de-
veloped atypical lymphocytes in the blood. These sera did not show rising
EBV antibody titers. In the recent study by Klemola, et al. on heterophile-
negative IM,1' patients with CMV-induced IM did not show booster re-
sponses in EBV antibodies despite a significant number of atypical lympho-
cytes in the peripheral blood.
Support for the second hypothesis would consist of demonstration of virus
in the leukocytes of a significant number of fetuses or newborn infants who
did not possess antibodies to EBV.
Does EBV cause Burkitt lymphomas, nasopharyngeal tumors or leukemia!
EBV-infected HLCL can be derived from individuals with diverse dis-
eases and from individuals without disease. There are at least three different
explanations that may account for these facts. First, in some diseases EBV
may play a causal role. Second, while causal in some diseases, in other in-
stances the passenger virus theory may be correct; EBV finds an appropri-
ate host cell in which to multiply with the appearance of lymphoblasts from
other causes. Third, since any infection with EBV may lead to life-long viral
persistence, the appearance of EBV in a given HLCL in vitro may merely
reflect past experience with the virus as well as the relative ease with which
the patient's lymphocytes can be grown in vitro.
An unresolved problem is how a single agent (or closely related agents?)
might cause a malignant lymphoma (BL) in one population and a benign
lymphoproliferative disease (IM) in another. Differences in viral strain,
differences in route of transmission, or differences in host factors might ac-
count for the high frequency of BL in Africa and its low frequency (com-
pared with IM) in America. Burkitt now suggests"8 that in some way the
co-existence of EBV and malaria might account for the high prevalence of
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BL in Africa. Epidemiologic evidence that might answer the question of
whether BL is caused by EBV is still lacking. A large scale prospective
serologic survey might determine for BL as it has for IM whether circulat-
ing antibodies are associated with protection from occurrence of the tumor.
Some have proposed that the only epidemiologic technique which will de-
termine whether BL is caused by EBV is mass vaccination in the epidemic
area against EBV followed by surveillance for BL.'
Patients with nasopharyngeal tumors have high antibody titers against
EBV' and EBV has been found in lymphoid cell lines derived from the
tumors."t The tumor, although worldwide, is most common in certain parts
of Africa and Asia. It is not histologically a lymphoid tumor, but a carci-
noma, heavily infiltrated with lymphoid cells. One might suppose that naso-
pharyngeal tumors call forth proliferation of lymphocytes in which EBV
persists. The situation may be analagous in sarcoid, in which high EBV
antibody titers have recently been recorded.'
Serologic studies have usually shown that leukemic children or leukemic
adults have comparable frequency of antibody and comparable antibody
titers to age-matched controls (see Table 2). However, data have not been
presented to indicate whether the sera tested were obtained from patients
under treatment with drugs that suppress the immune response. HLCL
have been derived from many patients with acute and chronic leukemia.
Some HLCL contain EBV particles and antigen, others have been free of
EBV. With the demonstration that EBV-negative cells may still contain
viral genome, it is still conceivable that EBV genetic material is associated
with leukemia cell lines, but that, for some reason, virion formation does
not proceed as well in leukemia cells as in cells from IM or BL. The co-
existence of acute leukemia, EBV infection and clinical IM has recently
been appreciated,' but the significance of this association remains to be
determined.
It appears that viral persistence, characteristic of the other members of
the herpes group in man, herpes simplex virus, varicella-zoster virus, and
cytomegalovirus, is also true for EBV. For example, although CMV may be
excreted by many healthy newborn infants,"2 the role of this agent as a
pathogen in a certain characteristic syndrome of congenital defects is not
questioned. The pattern that emerges from the group of human viral infec-
tions due to herpes viruses is one of prolonged association of the host and
virus with occasional production of disease.
Prospects for control of EBV infections
Before full-scale efforts to produce a vaccine or other control measures
for EBV infection are undertaken, the question whether the virus is indeed
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a human tumor virus must first be clarified. The most likely source for this
clarification will probably come from an animal system. Should evidence
point conclusively to an oncogenic role of EBV, control in the form of vac-
cination with an attenuated virus might be considered.
Several difficulties are immediately apparent upon consideration of a vac-
cine against EBV infections of man. It is unlikely that a vaccine could be
given to man in the form of infected intact and viable cells which might con-
tain other unknown potential tumor viruses. Hence, one technical prereq-
uisite for an EBV vaccine would be the production of significant amounts
of extracellular virus that could be purified. Utilization of an EBV vaccine
might be complicated by persistence of the vaccine virus and also, perhaps,
by persistence of virulent virus. Persistence of vaccine virus has been a
problem with the attenuated virus vaccine against Marek's disease.' Wheth-
er persistence of these viruses would result in harmful effects could only be
learned by long-term surveillance of vaccinated individuals.
As remote and difficult as seems the potential for control of EBV by vac-
cination, other methods appear equally complicated. Burkitt tumor appears
to be sensitive to chemotherapy with cyclophosphamide and longterm re-
missions have been reported, although drug resistance occurs.' The virus
might be expected to be sensitive to 5' iododeoxyuridine, a drug which has
been used to treat some infections with herpes simplex virus, but it might be
anticipated that virucidal doses of the drug given systemically would be high-
ly toxic. It seems unlikely that therapy with interferon or interferon inducers
would be of benefit. Cytomegaloviruses, the subgroup of the herpes group
of viruses most like EBV, are notably resistant to the action of interferon.'
Some novel approach might succeed that involved selective detection and
destruction of cells which have been transformed by EBV. One such method,
recently proposed by Moolten and Cooperband' would involve administra-
tion of antibody against EBV-induced membrane antigens. If this antibody
were also linked with a toxin capable of destroying cells (diphtheria toxin
in Moolten's in vitro experiments) all cells with the new membrane antigen
would be specifically eliminated. Another speculative approach which might
be termed "endogenous oncolysis" would be to devise a method which would
induce 100%o of EBV-transformed cells to undergo a lytic cycle of viral
replication and thus destroy themselves.
NOTE:
The bibliography, chosen to illustrate specific facets of investigations of EBV, is by
no means complete and was not compiled with the intention of indicating priority in any
aspect of research. A number of important topics have been excluded altogether from
the review, largely for lack of space. Such topics include the susceptibility of HLCL to
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superinfection with various viruses, the serologic cross-reactions among members of the
human and animal herpes viruses, and chromosome abnormalities in HLCL.
I am grateful to Professor Dorothy M. Horstmann for a critical reading and to Mrs.
Virginia Thompson and Miss Laurie Nicholson for help with the manuscript.
REFERENCES
1. Rous, P.: Transmission of a malignant new growth by means of a cell-free fil-
trate. J. Amer. med. Ass., 1911, 56, 198.
2. Gross, L.: "Spontaneous" leukemia developing in C3H mice following inoculation,
in infancy, with ak-leukemic extracts, or ak-embryos. Proc. Soc. exp. Biol.
(N.Y.), 1951, 78, 27-32.
3. Jarrett, W. F. H., Martin, W. B., Crighton, G. W., Dalton, R. G., and Stewart,
M. F.: Leukemia in the cat. Transmission experiments with leukemia (lympho-
sarcoma). Nature, 1964, 202, 566-567.
4. Trentin, J. J., Yabe, Y., and Taylor, G.: The quest for human cancer viruses.
Science, 1962, 137, 835-841.
5. Lucke, B.: Carcinoma in the leopard frog. Its probable causation by a virus. J.
exp. Med., 1938, 68, 457-468.
6. Fawcett, D. W.: Electronmicroscope observations of intracellular virus-like parti-
cles associated with the cells of the Lucke renal adenocarcinoma. J. Biophys.
Biochem. Cytol., 1956, 2, 725-742.
7. Mizell, M., Toplin, I., and Isaacs, J. J.: Tumor induction in developing frog kid-
neys by a zonal centrifuge purified fraction of the frog herpes-type virus. Sci-
ence, 1969, 165, 1134-1137.
8. Churchill, A. E., and Biggs, P. M.: Agent of Marek's disease in tissue culture.
Nature, 1967, 215, 528-530.
9. Churchill, A. E., Payne, L. N., and Chubb, R. C.: Immunization against Marek's
disease using a live attenuated virus. Nature, 1969, 221, 744-747.
10. Melendez, L. V., Hunt, R. D., Daniel, M. D., Garcia, F. G., and Fraser, C. E.
0.: Herpes virus saimiri II: Experimentally induced malignant lymphoma in
primates. Lab. Animal Care, 1969, 19, 378-386.
11. Rawls, W. E., Tomkins, W. A. F., Figueroa, M., and Melnick, J. L.: Herpes
virus type 2: Association with carcinoma of the cervix. Science, 1968, 161,
1255-1256.
12. Henle, G., Henle, W., and Diehl, V.: Relation of Burkitt's tumor-associated
herpes-type virus to infectious mononucleosis. Proc. nat. Acad. Sci. (Wash.),
1968, 59, 94-101.
13. Dameshek, W. and Gunz, F.: Leukemia. London, Grune and Stratton, 1964,
pp. 403-407.
14. Burkitt, D. P. and Wright, D. H. (ed.): Burkitt's Lymphoma. Edinburgh,
Livingstone, 1970.
15. Carter, R. L. and Penman, H. G. (ed.): Infectious Mononucleosis. Oxford,
Blackwell, 1969.
16. Burkitt, D.: A sarcoma involving the jaws in African children. Brit. J. Surg.,
1958, 46, 218-223.
17. Bell, T. M., Massie, A., Ross, M. G. R., and Williams, M. C.: Isolation of a
reovirus from a case of Burkitt's lymphoma. Brit. med. J., 1964, 1, 1212-1213.
18. Simons, P. J. and Ross, M. G. R.: The isolation of herpes virus from Burkitt
tumours. European J. Cancer, 1965, 1, 135-136.
19. Dalldorf, G. and Bergamini, F.: Unidentified, filtrable agents isolated from Afri-
can children with malignant lymphomas. Proc. nat. Acad. Sci. (Wash.), 1964,
51, 263-265.
20. Epstein, M. A. and Barr, Y. M.: Cultivation in vitro of human lymphoblasts
from Burkitt's malignant lymphoma. Lancet, 1964, i, 252-253.
21. Epstein, M. A., Barr, Y. M., and Achong, B. G.: A second virus-carrying tissue
culture strain (EB2) of lymphoblasts from Burkitt's lymphoma. Path. et Biol.,
1964, 12, 1233-1234.
379YALE JOURNAL OF BIOLOGY AND MEDICINE Volume 43, June, 1971
22. Epstein, M. A., Barr, Y. M., and Achong, B. G.: Studies on Burkitt's lymphoma:
Methodologic approaches to the study of leukemias. Wistar Inst. Symp.
Monogr., 1965, 4, 69-82.
23. Epstein, M. A., Achong, B. G., and Barr, Y. M.: Virus particles in cultured
lymphoblasts from Burkitt's lymphoma. Lancet, 1964, i, 702-703.
24. Pulvertaft, R. J. V.: Cytology of Burkitt's tumor (African lymphoma). Lancet,
1964, i, 238-240.
25. Stewart, S. E., Lovelace, E., Whang, J. J., and Ngu, V. A.: Burkitt tumor: Tis-
sue culture, cytogenetic and virus studies. J. nat. Cancer Inst., 1965, 34, 319-
327.
26. O'Conor, G. T. and Rabson, A. S.: Herpes-like virus particles in an American
lymphoma. Preliminary note. J. nat. Cancer Inst., 1965, 35, 899-933.
27. Epstein, M. A., Achong, B. G., Barr, Y. M., Zajac, B., Henle, G., and Henle, W.:
Morphological and virological investigations on cultured Burkitt tumor lympho-
blasts (strain Raji). J. nat. Cancer Inst., 1966, 37, 547-559.
28. Ikawata, S. and Grace, J. T., Jr.: Cultivation in vitro of myeloblasts from human
leukemia. N.Y. St. J. Med., 1964, 64, 2279-2282.
29. Foley, G. E., Lazarus, H., Farber, S., Uzman, B. G., Boone, B. A., and McCarthy,
R. E.: Continuous culture of human lymphoblasts from peripheral blood of a
child with acute leukemia. Cancer, 1965, 18, 522-529.
30. Moore, G. E., Grace, J. T., Citron, P., Gerner, R., and Burns, A.: Leukocyte
cultures of patients with leukemia and lymphomas. N.Y. St. J. Med., 1966, 66,
2757-2764.
31. Armstrong, D.: Serial cultivation of human leukemic cells. Proc. Soc. exp. Biol.
(N.Y.), 1966, 122, 475-481.
32. Zeve, V. H., Lucas, S. L., and Manaker, R. A.: Continuous cell culture from a
patient with chronic myelogenous leukemia. II. Detection of a herpes-like virus
by electronmicroscopy. J. nat. Cancer Inst., 1966, 37, 761-773.
33. Clarkson, B., Strife, A., and de Harven, E.: Continuous cultures of seven new
lines (SKL-1-7) from patients with acute leukemia. Cancer, 1967, 20, 926-946.
34. Jensen, E. M., Korol, W., Dittmar, S. L., and Medrek, T. J.: Virus containing
lymphocyte cultures from cancer patients. J. nat. Cancer Inst., 1967, 39, 745-
754.
35. Levy, J. A., Virolainen, M., and Defendi, V.: Human lymphoblastoid lines from
lymph node and spleen. Cancer, 1968, 22, 517-524.
36. Pope, J. H.: Establishment of cell lines from peripheral leukocytes in infectious
mononucleosis. Nature, 1967, 216, 810-811.
37. Glade, P. R., Kasel, J. A., Moses, H. L., Whang-Peng, J., Hoffman, P. F., Kam-
mermeyer, J. K., and Chessin, L. N.: Infectious mononucleosis: Continuous
suspension culture of peripheral blood- leukocytes. Nature, 1968, 217, 564-565.
38. Diehl, V., Henle, G., Henle, W., and Kohn, G.: Demonstration of a herpes group
virus in cultures of peripheral leukocytes from patients with infectious mono-
nucleosis. J. Virol., 1968, 2, 663-669..
39. Moses, H. L., Glade, P. R., Kasel, J. A., Rosenthal, A. S., Hirshaut, Y., and
Chessin, L. N.: Infectious mononucleosis-Detection of herpes-like virus and
reticular aggregates of small cytoplasmic particles in continuous lymphoid cell
lines derived from peripheral blood. Proc. nat. Acad. Sci. (Wash.), 1968, 60,
489-496.
40. Glade, P. R., Hirshaut, Y., Douglas, S. D., and Hirshhorn, K.: Lymphoid sus-
pension cultures from patients with viral hepatitis. Lancet, 1968, ii, 1273-1275.
41. Stevens, D. P., Barker, L. F., Fike, R., Hopps, H. E. and Meyer, H. M., Jr.:
Lymphoblastoid cell cultures from patients with infectious hepatitis. Proc. Soc.
exp. Biol. (N.Y.), 1969, 132, 1042-1046.
42. Minnefor, A. B., Halstead, C. C., Seto, D. S. Y., Glade, P. R., Moore, G. E., and
Carver, D. H.: Production of interferon by long-term suspension cultures of
leukocytes derived from patients with viral and non-viral diseases. J. infect.
Dis., 1970,121, 442-444.
43. Klemola, E., von Essen, R., Wager, O., Haltia, K, Koivuniemi, A., and Salmi,
I.: Cytomegalovirus mononucleosis in previously healthy individuals. Ann.
intern. Med., 1969, 71, 11-19.
380E-B virus, a review I MILLER
44. Moore, G. E., Gerner, R. E., and Franklin, H. A.: Culture of normal human
leukocytes. J. Amer. med. Ass., 1967, 199, 519-524.
45. Gerber, P. and Monroe, J. H.: Studies on leukocytes growing in continuous cul-
ture derived from normal human donors. J. nat. Cancer Inst., 1968, 40, 855-866.
46. Zur Hausen, H. and Schulte-Holthausen, H.: Presence of EB virus nucleic acid
homology in a "virus-free" line of Burkitt tumor cells. Nature, 1970, 227, 245-
248.
47. Epstein, M. A., Henle, G., Achong, B. G., and Barr, Y. M.: Morphological and
biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma.
J. exp. Med., 1965, 121, 761-770.
48. Toplin, I. and Schidlovsky, G.: Partial purification and electronmicroscopy of
virus in the EB-3 cell line derived from a Burkitt lymphoma. Science, 1966,
152, 1084-lO05.
49. Weinberg, A. and Becker, Y.: Studies on EB virus of Burkitt's lymphoblasts.
Virology, 1969, 39, 312-321.
50. Schulte-Holthausen, H. and Zur Hausen, H.: Partial purification of the Epstein-
Barr virus and some properties of its DNA. Virology, 1970, 40, 776-779.
51. Wagner, E. K., Roizman, B., Savage, T., Spear, P. G., Mizell, M., Durr, F. E.,
and Sypowicz, D.: Characterization of the DNA of herpes viruses associated
with Lucke adenocarcinoma of the frog and Burkitt lymphoma of man. Virol-
ogy, 1970, 42, 257-261.
52. Hinuma, Y., Konn, M., Yamaguchi, J., and Grace, J. T.: Replication of herpes-
type virus in a Burkitt lymphoma cell line. J. Virol., 1967,1, 1203-1206.
53. Henle, G. and Henle, W.: Immunofluorescence in cells derived from Burkitt's
lymphoma. J. Bact., 1966, 91, 1248-1256.
54. Epstein, M. and Achong, B.: Specific immunofluorescence test for the herpes-
type EB virus of Burkitt lymphoblasts, authenticated by EM. J. nat. Cancer
Inst., 1968, 40, 593-607.
55. Zur Hausen, H., Henle, W., Hummeler, K., Diehl, V., and Henle, G.: Compara-
tive study of cultured Burkitt tumor cells by immunofluorescence, autoradiog-
raphy, and electronmicroscopy. J. Virol., 1967,1, 830-837.
56. Klein, G., Clifford, P., Klein, E., and Stjernsward, J.: Search for tumor specific
immune reactions in Burkitt lymphoma patients by the membrane immuno-
fluorescence reaction. Proc. nat. Acad. Sci. (Wash.), 1966, 55, 1628-1635.
57. Klein, G., Clifford, P., Klein, E., Smith, R. T., Minowada, J., Kourilsky, F., and
Burchenal, J. H.: Membrane immunofluorescence reactions of Burkitt lympho-
ma cells from biopsy specimens and tissue cultures. J. nat. Cancer Inst., 1967,
39, 1027-1044.
58. Svedmyr, A., Demissie, A., Klein, G., and Clifford, P.: Antibody patterns in dif-
ferent human sera against intracellular and membrane-antigen complexes as-
sociated with Epstein-Barr virus. J. nat. Cancer Inst., 1970, 44, 595-610.
59. Pearson, G., Klein, G., Henle, G., Henle, W., and Clifford, P.: Relation between
Epstein-Barr viral and cell membrane immunofluorescence in Burkitt tumor
cells. IV. Differentiation between antibodies responsible for membrane and
viral immunofluorescence. J. exp. Med., 1969, 129, 707-718.
60. Klein, G., Pearson, G., Nadkarni, J. S., Nadkarni, J. J., Klein, E., Henle, G.,
Henle, W., and Clifford, P.: Relations between Epstein-Barr viral and cell
membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell
membrane immunofluorescence on presence of EB virus. J. exp. Med., 1968,
128, 1011-1020.
61. Baranska, W., Koldovsky, P., and Koprowski, H.: Antigenic study of unfertilized
mouse eggs: cross reactivity with SV40-induced antigens. Proc. nat. Acad. Sci.
(Wash.), 1970, 67, 193-199.
62. Gerber, P., and Birch, S. M.: Complement-fixing antibodies in sera of humans
and non-human primates to viral antigens derived from Burkitt lymphoma
cells. Proc. nat. Acad. Sci. (Wash.), 1967, 58, 478-484.
63. Armstrong, D., Henle, G., and Henle, W.: Complement fixation tests with cell
lines derived from Burkitt's lymphoma and acute leukemias. J. Bact., 1966, 91,
1257-1262.
381YALE JOURNAL OF BIOLOGY AND MEDICINE Volume 43, June, 1971
64. Gerber, P. and Deal, D. R.: Epstein-Barr virus-induced viral and soluble com-
plement-fixing antigens in Burkitt lymphoma cell cultures. Proc. Soc. exp.
Biol. (N.Y.), 1970,134, 748-751.
65. Vonka, J., Benyesh-Melnick, M., and McCombs, R. M.: Antibodies in human sera
to soluble and viral antigens found in Burkitt lymphoma and other lympho-
blastoid cell lines. J. nat. Cancer Inst., 1970, 44, 865-872.
66. Old, L. J., Boyse, E. A., Oettgen, H. F., De Harven, E., Geering, G., Williamson,
B., and Clifford, P.: Precipitating antibody in human serum to an antigen
present in cultured Burkitt's lymphoma cells. Proc. nat. Acad. Sci. (Wash.),
1966, 56, 1699-1704.
67. Stevens, D. A., Pry, J. W., and Blackham, E. A.: Prevalence of precipitating
antibody to antigens derived from Burkitt lymphoma cultures infected with
herpes-type virus (EB virus). Blood, 1970, 35, 263-275.
68. Immunology Subgroup. Special Virus-Cancer Program: Results of a comparison
of serologic tests to detect human antibodies to a herpes virus (HLV) associ-
ated with Burkitt's lymphoma. J. nat. Cancer Inst., 1969, 42, 623-631.
69. Henle, W., Diehl, V., Kohn, G., Zur Hausen, H., and Henle, G.: Herpes-type
virus and chromosome marker in normal leukocytes after growth with irradi-
ated Burkitt cells. Science, 1967, 157, 1064-1065.
70. Miller, G., Enders, J. F., Lisco, H., and Kohn, H. L.: Establishment of lines
from normal human blood leukocytes by co-cultivation with a leukocyte line
derived from a leukemic child. Proc. Soc. exp. Biol. (N.Y.), 1969, 132, 247-252.
71. Miller, G., Lisco, H., Kohn, H. L., and Stitt, D.: Establishment of cell lines from
normal adult blood leukocytes by exposure to Epstein-Barr virus and neu-
tralization by human sera with Epstein-Barr virus antibody. Proc. Soc. exp.
Biol. (N.Y.), in press.
72. Diehl, V., Henle, G., Henle, W., and Kohn, G.: Effect of a herpes group virus
(EBV) on growth of peripheral leukocyte cultures. Hemic Cells in Vitro,
1969, 4, 92-99.
73. Pope, J. H., Horne, M. K., and Scott, W.: Transformation of foetal human
leukocytes in vitro by filtrates of a human leukemic cell line containing herpes-
like virus. Int. J. Cancer, 1968, 3, 857-866.
74. Pope, J. H., Horne, M. K., and Scott, W.: Identification of the filtrable leuko-
cyte-transforming factor of QIMR-WIL cells as herpes-like virus. Int. J. Can-
cer, 1969, 4, 255-260.
75. Gerber, P., Whang-Peng, J., and Monroe, J. H.: Transformation and chromo-
some changes induced by Epstein-Barr virus in normal human leukocyte cul-
tures. Proc. nat. Acad. Sci. (Wash.), 1969, 63, 740-747.
76. Hinz, R. W., Bowles, C. A., Conner, G. H., Mitchell, J. R., and Anderson, G. R.:
Characterization of a herpes-like virus recovered from Burkitt lymphoma cells
(P3-J) and propagated in dog thymus cells: An EM study. J. nat. Cancer
Inst., 1968, 40, 477-489.
77. Stewart, S. E.: Biological activity of the virus in the Burkitt tumor SLi cell
line trans, Trans. N.Y. Acad. Sci., 1965, 28, 291-301.
78. Horoszewicz, J. S., Dunkel, V. C., and Grace, J. T.: Biological properties of a
herpes-like virus (HLV) from Burkitt lymphoma cell line. Fed. Proc., 1968,
27, 262.
79. Durr, F. E., Traul, K. A., Schmitter, R., and Monroe, J. H.: In vitro bioassay of
Epstein-Barr virus. Bact. Proc., 1970, p. 195. (Abstract)
80. Pearson, G., Dewey, F., Zajac, B., Henle, G., and Henle, W.: Studies on EB
virus infection of cultured lymphoblastoid cell lines. Bact. Proc., 1970, p. 195
(Abstract).
81. Henle, W., Henle, G., Zajac, B. A., Pearson, G., Waubke, R., and Scriba, M.:
Differential reactivity of human serums with early antigens induced by Epstein-
Barr virus. Science, 1970, 169, 188-190.
82. Hinuma, Y., Konn, M., Yamaguchi, J., Wudarski, D. J., Blakeslee, J. R., and
Grace, J. T., Jr.: Immunofluorescence and herpes-type virus particles in the
P3HR-1 Burkitt lymphoma cell line. J. Virol., 1967, 1, 1045-1051.
83. Henle, W. and Henle, G.: Effect of arginine-deficient media on the herpes-type
virus associated with cultured Burkitt tumor cells. J. Virol., 1968, 2, 182-191.
84. Zajac, B. A., Henle, W., and Henle, G.: Autogenous and virus-induced inter-
ferons from lines of lymphoblastoid cells. Cancer Res., 1969, 29, 1467-1475.
382E-B virus, a review I MILLER
85. Zajac, B. A., and Kohn, G.: Epstein-Barr virus antigens, marker chromosome,
and interferon production in clones derived from cultured Burkitt tumor cells.
J. nat. Cancer Inst., 1970, 45, 399-406.
86. Maurer, B. A., and Wilbert, S. M.: EB virus production by progeny of single
Burkitt lymphoma cells. Bact. Proc., 1970, p. 195. (Abstract)
87. Miller, M. H., Stitt, D., and Miller, G.: Epstein-Barr viral antigen in single cell
clones of two human leukocytic lines. J. Virol., 1970, 6, 699-701.
88. Southam, C. M., Burhenal, J. H., Clarkson, B., Tanzi, A., Mackey, R., and Mc-
Comb, V.: Heterotransplantation of human cell lines from Burkitt's tumors
and acute leukemia into newborn rats. Cancer, 1969, 23, 281-299.
89. Adams, R. A., Foley, G. E., Uzman, B. G., Farber, S., Lazarus, H., and Kleinman,
L.: Leukemia-serial transplantation of human leukemic lymphoblasts in the
newborn Syrian hamster. Cancer Res., 1967, 27, 772-783.
90. Adams, R. A., Foley, G. E., Farber, S., Flowers, A., Lazarus, H., and Heller-
stein, E.: Serial transplantation of Burkitt's tumor (EB3) cells in newborn
Syrian hamsters and its facilitation by antilymphocyte serum. Cancer Res.,
1970, 30, 338-345.
91. Klein, G., Pearson, G., Henle, G., Henle, W., Diehl, V., and Niederman, J. C.:
Relation between Epstein-Barr viral and cell membrane immunofluorescence in
Burkitt tumor cells. II. Comparison of cells and sera from patients with
Burkitt's lymphoma and infectious mononucleosis. J. exp. Med., 1968, 128, 1021-
1030.
92. Klein, G., Clifford, P., Henle, G., Henle, W., Geering, G., and Old, L. J.: EBV-
associated serological patterns in a Burkitt lymphoma patient during regression
and recurrence. Int. J. Cancer, 1969, 4, 416-421.
93. Fass, L., Herberman, R. B., and Ziegler, J.: Delayed cutaneous hypersensitivity
reactions to autologous extracts of Burkitt-lymphoma cells. New Engl. J. Med.,
1970, 282, 776-780.
94. Steele, G. M. and Hardy, D. A.: Evidence of altered antigenicity in cultured
lymphoid cells from patients with infectious mononucleosis. Lancet, 1970, i,
1322-1323.
95. Junge, U., Hoekstra, J., and Deinhardt, F.: Altered antigenicity of cultured
mononucleosis lymphocytes. Lancet, 1970, ii, 217.
96. Gerber, P. and Rosenblum, E. N.: The incidence of complement-fixing antibodies
to herpes simplex and herpes-like viruses in man and Rhesus monkeys. Proc.
Soc. exp. Biol. (N.Y.), 1968, 128, 541-546.
97. Porter, D. D., Wimberly, I., and Benyesh-Melnick, M.: Prevalence of antibodies
to EB virus and other herpes viruses. J. Amer. med. Ass., 1969, 208, 1675-1679.
98. Henle, G. and Henle, W.: Observations on childhood infections with the Epstein-
Barr virus. J. infect. Dis., 1970, 121, 303-310.
99. Henle, G., Henle, W., Clifford, P., Diehl, V., Kafuko, G. W., Kiryza, B. G.,
Klein, G., Morrow, R. H., Munube, G. M. R., Pike, P., Tukei, P. M., and
Ziegler, J. L.: Antibodies to Epstein-Barr virus in Burkitt's lymphoma and
control groups. J. nat. Cancer Inst., 1969, 43, 1147-1157.
100. Evans, A. S., Niederman, J. C., and McCollum, R. W.: Sero epidemiologic studies
of infectious mononucleosis with EB virus. New Engl. J. Med., 1968, 279, 1121-
1127.
101. Evans, A. S.: Infectious mononucleosis in University of Wisconsin students.
Amer. J. Hyg., 1960, 71, 342-362.
102. Niederman, J. C., Evans, A. S., Subrahmanyan, L., and McCollum, R. W.:
Prevalence, incidence and persistence of EB virus antibody in young adults.
New Engl. J. Med., 1970, 282, 361-365.
103. Levy, J. A. and Henle, G.: Indirect immunofluorescence tests with sera from
African children and cultured Burkitt lymphoma cells. J. Bact., 1966, 92, 275-
276.
104. Gerber, P., Hamre, D., Moy, R. A., and Rosenblum, E. N.: Infectious mono-
nucleosis: Complement-fixing antibodies to herpes-like virus associated with
Burkitt lymphoma. Science, 1968, 161, 173-175.
105. Niederman, J. C., McCollum, R. W., Henle, G., and Henle, W.: Infectious mono-
nucleosis-clinical manifestations in relation to EB virus antibodies. J. Amer.
med. Ass., 1968, 203, 205-209.
383YALE JOURNAL OF BIOLOGY AND MEDICINE Volume 43, June, 1971
106. Hirshaut, Y., Glade, P. R., Moses, H., Manaker, R., and Chessin, L. N.: Associ-
ation of herpes-like virus infection with infectious mononucleosis. Amer. J.
Med., 1969, 47, 520-527.
107. Klemola, E. and Kaariainen, L.: Cytomegalovirus as possible cause of disease
resembling infectious mononucleosis. Brit. med. J., 1965, 2, 1099-1102.
108. Klemola, E., von Essen, R., Henle, G., and Henle, W.: Infectious mononucleosis-
like disease with negative heterophile agglutination test. Clinical features in re-
lation to Epstein-Barr virus and cytomegalovirus antibodies. J. infect. Dis.,
1970, 121, 608-614.
109. Gerber, P., Walsh, J. N., Rosenblum, E. N., and Purcell, R. H.: Association of
EB virus infection with the post-perfusion syndrome. Lancet, 1969, i, 593-596.
110. Blacklow, N. R., Watson, B. K., Miller, G., and Jacobson, B. M.: Mononucleosis
with heterophile antibodies and EB virus infection acquired by an elderly pa-
tient in hospital. Amer. J. Med. (in press).
111. Henle, W., Henle, G., Scriba, M., Joyner, C. R., Harrison, F. S., von Essen, R.,
Paloheimo, J., and Klemola, E.: Antibody responses to the Epstein-Barr virus
and cytomegaloviruses after open-heart and other surgery. New Engl. J. Med.,
1970, 282, 1068-1074.
112. Wheelock, E. F.: Interferon-like virus inhibitor induced in human leukocytes by
phytohemagglutinin. Science, 1965, 149, 310-311.
113. Swart, B. E. and Young, B. G.: Inverse relationship of interferon production and
virus content in cell lines from Burkitt's lymphoma and acute leukemias. J.
nat. Cancer Inst., 1969, 42, 941-944.
114. Matsuoka, Y., Takahashi, M., Yagi, Y., Moore, G. E., and Pressman, D.: Syn-
thesis and secretion of immunoglobulins by established cell lines of human
hematopoietic origin. J. Immunol., 1968, 101, 1111-1120.
115. Moore, G. E.: Working with human cell lines. Lancet, 1970, ii, 978-979.
116. Payne, F. E., Baublis, J. V., and Itabashi, H. H.: Isolation of measles virus from
cell cultures of brain from a patient with subacute sclerosing panencephalitis.
New Engl. J. Med., 1969, 281, 585-589.
117. McCollum, R. W., Niederman, J. C., Evans, A. S., and Giles, J. P.: Viruses in
viral hepatitis. Lancet, 1969, i, 778-779.
118. Burkitt, D. P.: Etiology of Burkitt's lymphoma-an alternative hypothesis to a
vectored virus. J. nat. Cancer Inst., 1969, 42, 19-28.
119. Epstein, M. A.: Aspects of the EB virus. Advanc. Cancer Res., 1970, 13, 383-411.
120. Henle, W., Henle, G., Ho, H. C., Burtin, P., Cachin, Y., Clifford, P., de Schryver,
A., de-The, G., Diehl, V., and Klein, G.: Antibodies to Epstein-Barr virus in
nasopharyngeal carcinoma, other head and neck neoplasms and control groups.
J. nat. Cancer Inst., 1970, 44, 225-231.
121. de-The, G., Amrosioni, J. C., Ho, H. C., and Kwan, H. C.: Lymphoblastoid
transformation and presence of herpes-type viral particles in a Chinese naso-
pharyngeal tumor cultured in vitro. Nature, 1969, 221, 770-771.
122. Hirshaut, Y., Glade, P., Viera, L. 0. B. D., Ainbender, E., Dvorak, B. and Siltz-
bach, L. E.: Sarcoidosis, another disease associated with serologic evidence for
herpes-like virus infection. New Engl. J. Med., 1970, 283, 502-506.
123. Deardorff, W. L., Gerber, P., and Vogler, W. R.: Infectious mononucleosis in
acute leukemia with rising Epstein-Barr virus antibody titers. Ann. intern.
Med., 1970, 72, 235-240.
124. Starr, J. G., Bart, R. D., and Gold, E.: Inapparent congenital cytomegalovirus
infection: clinical and epidemiologic characteristics in early infancy. New Engl.
J. Med., 1970, 282, 1075-1078.
125. Nazerian, K.: Attenuation of Marek's disease virus and study of its properties in
two different cell cultures. J. nat. Cancer Inst., 1970, 44, 1257-1267.
126. Carbone, P., Bernard, C. W., Bennett, J. M., Ziegler, J. L., Cohen, M. H., and
Gerber, P.: National Institutes of Health Clinical Staff Conference: Burkitt's
tumor. Ann. intern. Med., 1969, 70, 817-832.
127. Osborn, J. E., and Medearis, D. N., Jr.: Studies of relationship between mouse
cytomegalovirus and interferon. Proc. Soc. exp. Biol. (N.Y.), 1966, 121, 819-
824.
128. Moolten, F. L. and Cooperband, S. R.: Selective destruction of target cells by
diphtheria toxin conjugated to antibody directed against antigens on the cells.
Science, 1970, 169, 68-70.
384